

# INPLASY PROTOCOL

To cite: Yang et al. The impact of platinum-containing chemotherapies in advanced triple-negative breast cancer: meta-analytical approach to evaluating its efficacy and safety. Inplasy protocol 202110070. doi: 10.37766/inplasy2021.1.0070

Received: 19 January 2021

Published: 19 January 2021

**Corresponding author:**  
Sheng Liu

yshtcm@163.com

**Author Affiliation:**  
Institute of Chinese Traditional Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine

**Support:** National Natural Science Found.

**Review Stage at time of this submission:** Data analysis.

**Conflicts of interest:**  
None.

## The impact of platinum-containing chemotherapies in advanced triple-negative breast cancer: meta-analytical approach to evaluating its efficacy and safety

Yang, R<sup>1</sup>; Shi, YY<sup>2</sup>; Han, XH<sup>3</sup>; Liu, L<sup>4</sup>.

**Review question / Objective:** (1) participants: patients received a definitive diagnosis of advanced TNBC by pathology or cytology; (2) interventions and comparisons: intervention groups received platinum-containing chemotherapy and control groups received either non-platinum-containing or platinum-containing chemotherapy combined with target drugs. Whether the blind method was not limit. Basic conditions between the two groups were similar and comparable; (3) outcomes: PFS, OS, ORR, and side effects were evaluated in this study.

**Condition being studied:** Advanced triple-negative breast cancer.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 19 January 2021 and was last updated on 19 January 2021 (registration number INPLASY202110070).

### INTRODUCTION

**Review question / Objective:** (1) participants: patients received a definitive diagnosis of advanced TNBC by pathology or cytology; (2) interventions and comparisons: intervention groups received

platinum-containing chemotherapy and control groups received either non-platinum-containing or platinum-containing chemotherapy combined with target drugs. Whether the blind method was not limit. Basic conditions between the two groups were similar and comparable; (3)

---

outcomes: PFS, OS, ORR, and side effects were evaluated in this study.

**Condition being studied:** Advanced triple-negative breast cancer.

## METHODS

**Participant or population:** Patients received a definitive diagnosis of advanced TNBC by pathology or cytology.

**Intervention:** platinum-containing chemotherapies in advanced triple-negative breast cancer.

**Comparator:** Non-platinum-containing chemotherapies in advanced triple-negative breast cancer

**Study designs to be included:** Published randomized controlled clinical studies of platinum-containing chemotherapies for advanced TNBC before November.

**Eligibility criteria:** To collect published randomized controlled clinical studies of platinum-containing chemotherapies for advanced TNBC before November 2020.

**Information sources:** PubMed, Medline, Embase, Clinicaltrials.gov, Cochrane Library, CNKI, CBM, and the Chinese Cochrane Center.

**Main outcome(s):** Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and side effects were evaluated in this study.

**Quality assessment / Risk of bias analysis:** (1) random sequence generation (selection bias); (2) allocation concealment (selection bias); (3) blinding of participants, personnel, and outcome assessment (performance bias and detection bias); (4) incomplete outcome data (attrition bias); (5) selective reporting data (reporting bias).

**Strategy of data synthesis:** Review Manager v5.3 was used for data analysis. The I<sup>2</sup> test was used for quantitative analysis of interstudy statistical heterogeneity. Generally, an I<sup>2</sup> > 50%

indicates substantial heterogeneity, and thus, a random-effect model should be used. When there is no evidence of statistical heterogeneity among studies (I<sup>2</sup> < 50%), a fixed-effect model should be used for the meta-analysis.

**Subgroup analysis:** For dichotomous outcomes (adverse events).

**Sensibility analysis:** None.

**Country(ies) involved:** China.

**Keywords:** Advanced triple-negative breast cancer, Metastatic, Platinum, Chemotherapy, Meta-analysis.

### Contributions of each author:

Author 1 - Rui Yang.

Author 2 - You-yang Shi.

Author 3 - Xiang-hui Han.

Author 4 - Sheng Liu.